Mymetics Corp (MYMX)

[bow-tie]

Check out the ref:

Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.
Asadi K1, Gholami A2
Author information
International Journal of Biological Macromolecules, 15 Apr 2021, 182:648-658
DOI: 10.1016/j.ijbiomac.2021.04.005 PMID: 33862071
Review

Share this article Share with emailShare with twitterShare with linkedinShare with facebook
Abstract
Vaccination is the most effective means of controlling infectious disease-related morbidity and mortality. However, due to low immunogenicity of viral antigens, nanomedicine as a new opportunity in new generation of vaccine advancement attracted researcher encouragement. Virosome is a lipidic nanomaterial emerging as FDA approved nanocarriers with promising bioinspiration and biomimetic potency against viral infections. Virosome surface modification with critical viral fusion proteins is the cornerstone of vaccine development. Surface antigens at virosomes innovatively interact with targeted receptors on host cells that evoke humoral or cellular immune responses through antibody-producing B cell and internalization by endocytosis-mediated pathways. To date, several nanovaccine based on virosome formulations have been commercialized against widespread and life-threatening infections. Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.
Full text links
Read article for free, from open access legal sources, via Unpaywall: https://doi.org/10.1016/j.ijbiomac.2021.04.005Unpaywall

Read article at publisher's site (DOI): 10.1016/j.ijbiomac.2021.04.005

References
Articles referenced by this article (88)

Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.
Jazayeri SD, Poh CL
Vaccines (Basel), (4) 2019

MED: 31683888

A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, Zurbriggen R
Vaccine, (41):7065-7074 2007

MED: 17766014

https://europepmc.org/article/MED/33862071